For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer
General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126 (Public Relations)
: +81-3-6225-1125 (Investor Relations)

Daiichi Sankyo Files for Approval to Manufacture and Market AMG 162 (Denosumab) in Japan

Tokyo, Japan (August 25, 2010) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has filed for approval in Japan to manufacture and market AMG 162 (Denosumab), a gene recombinant drug for bone disorders stemming from bone metastases.

Denosumab is the world's first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation. Daiichi Sankyo has been working on Denosumab since 2007, when it acquired the rights from Amgen Inc. to develop and market this antibody in Japan.

In addition, Daiichi Sankyo is conducting a Phase III clinical trial for Denosumab to treat osteoporosis in Japan.

In Denosumab, Daiichi Sankyo aims to benefit patients, their families, and medical professionals by augmenting the few available therapeutic alternatives for treating disorders stemming from cancer-related bone metastases with a new and effective treatment option.

###